2014
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
Zahr A, Aldin E, Komrokji RS, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal Of Blood Medicine 2014, Volume 6: 1-16. PMID: 25565910, PMCID: PMC4278786, DOI: 10.2147/jbm.s50482.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyelodysplastic syndromeClinical trialsClinical utilityRed blood cell transfusion requirementsLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeActivity of lenalidomideDifferent prognostic scoresMajor clinical trialsPeripheral blood cytopeniasEfficacy of lenalidomideClonal hematopoietic disordersQuality of lifeMechanism of actionMDS managementTransfusion requirementsBlood cytopeniasPrognostic scoreClinical outcomesRisk stratificationMechanisms of resistanceIneffective hematopoiesisLenalidomideDrug lenalidomideLeukemic transformation
2013
P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine
Zeidan A, Zhuoxin S, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine. Leukemia Research 2013, 37: s79-s80. DOI: 10.1016/s0145-2126(13)70172-3.Peer-Reviewed Original Research